Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype : study protocol for a randomized double-blind placebo-controlled trial
Background: Glioblastoma, IDH wildtype is the most common primary malignant brain tumor in adults. Despite best available treatment, prognosis remains poor. Current standard therapy consists of surgical tumor removal followed by radiotherapy and chemotherapy with the alkylating agent temozolomide. Antisecretory factor (AF), an endogenous protein, may potentiate the effect of temozolomide and allev
